NCT00900874

Brief Summary

The hypothesis of this study is that the onset of rapid bronchodilatory effect of inhaled Formoterol (12 microgram) is comparable to that of inhaled salbutamol (200 microgram) i.e., the difference in mean forced expiratory volume in 1 second (FEV1) between the 2 groups at 1, 5, 10, 30 and 60 minutes will be less than 10% in children between 5-15 years with mild acute exacerbation of asthma.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
78

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2009

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 12, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 13, 2009

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

May 13, 2009

Status Verified

May 1, 2009

Enrollment Period

1.3 years

First QC Date

May 12, 2009

Last Update Submit

May 12, 2009

Conditions

Keywords

FormoterolRapid bronchodilation

Outcome Measures

Primary Outcomes (1)

  • Difference in mean FEV1 between the two groups at 1, 5, 10, 30, 60 minutes

    60 min

Secondary Outcomes (3)

  • Difference in average clinical asthma score between two groups

    60 min

  • Adverse effects like tremors, vomiting, palpitation, etc, in two groups

    60 mins

  • Number of patients requiring hospitalization in two groups at end of study period in two groups

    60 min

Study Arms (2)

1

ACTIVE COMPARATOR

Salbutamol + steroid

Drug: salbutamol

2

ACTIVE COMPARATOR

Formoterol + steroid

Drug: Formoterol

Interventions

two puffs (100 microgram each of salbutamol) by MDI and spacer

1

Formoterol 2 puffs (6 µg /puff) by MDI and spacer

2

Eligibility Criteria

Age5 Years - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children aged 5-15 years of either sex seeking treatment with mild exacerbation of asthma in pediatric chest clinic or Pediatric OPD
  • Mild exacerbation will be defined as:
  • children presenting with increase in symptoms (cough, wheeze, breathlessness) for less than 7 days duration
  • no chest indrawing
  • no difficulty in speech
  • clinical asthma score (or pulmonary index score-annexure 1) between 6-9

You may not qualify if:

  • Children with life threatening asthma detected by presence of any of the following:
  • severe chest indrawing
  • cyanosis
  • irregular respiration
  • altered sensorium
  • Children with other chronic respiratory conditions like tuberculosis, cystic fibrosis or other acute illness that would complicate current treatment and response for asthma
  • If child has taken salbutamol in last 6 hours or if he is on long acting beta agonists (formoterol or salmeterol)
  • Child not able to perform spirometry
  • Parents refusing to give consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AIIMS

New Delhi, New Delhi, 110029, India

RECRUITING

Related Publications (1)

  • Arun JJ, Lodha R, Kabra SK. Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial. BMC Pediatr. 2012 Mar 7;12:21. doi: 10.1186/1471-2431-12-21.

MeSH Terms

Conditions

Asthma

Interventions

AlbuterolFormoterol Fumarate

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesPhenethylaminesEthylamines

Central Study Contacts

S.K Kabra, Dr

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 12, 2009

First Posted

May 13, 2009

Study Start

January 1, 2009

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

May 13, 2009

Record last verified: 2009-05

Locations